JP2012506911A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012506911A5 JP2012506911A5 JP2011534697A JP2011534697A JP2012506911A5 JP 2012506911 A5 JP2012506911 A5 JP 2012506911A5 JP 2011534697 A JP2011534697 A JP 2011534697A JP 2011534697 A JP2011534697 A JP 2011534697A JP 2012506911 A5 JP2012506911 A5 JP 2012506911A5
- Authority
- JP
- Japan
- Prior art keywords
- controlled release
- release formulation
- diacerein
- formulation
- weight
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 claims 34
- 238000009472 formulation Methods 0.000 claims 33
- 238000013270 controlled release Methods 0.000 claims 22
- TYNLGDBUJLVSMA-UHFFFAOYSA-N 4,5-diacetyloxy-9,10-dioxo-2-anthracenecarboxylic acid Chemical compound O=C1C2=CC(C(O)=O)=CC(OC(C)=O)=C2C(=O)C2=C1C=CC=C2OC(=O)C TYNLGDBUJLVSMA-UHFFFAOYSA-N 0.000 claims 15
- 229960004590 diacerein Drugs 0.000 claims 15
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims 6
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims 5
- 229930195725 Mannitol Natural products 0.000 claims 5
- 239000000594 mannitol Substances 0.000 claims 5
- 235000010355 mannitol Nutrition 0.000 claims 5
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 claims 4
- 230000036470 plasma concentration Effects 0.000 claims 4
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims 4
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims 4
- 229940069328 povidone Drugs 0.000 claims 4
- 239000004480 active ingredient Substances 0.000 claims 3
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims 3
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims 3
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims 3
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims 3
- 235000019359 magnesium stearate Nutrition 0.000 claims 3
- 208000023275 Autoimmune disease Diseases 0.000 claims 2
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims 2
- 206010012601 diabetes mellitus Diseases 0.000 claims 2
- 230000000694 effects Effects 0.000 claims 2
- 208000027866 inflammatory disease Diseases 0.000 claims 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims 2
- 239000008108 microcrystalline cellulose Substances 0.000 claims 2
- 229940016286 microcrystalline cellulose Drugs 0.000 claims 2
- 239000005541 ACE inhibitor Substances 0.000 claims 1
- 102000008873 Angiotensin II receptor Human genes 0.000 claims 1
- 108050000824 Angiotensin II receptor Proteins 0.000 claims 1
- 101710129690 Angiotensin-converting enzyme inhibitor Proteins 0.000 claims 1
- 101710086378 Bradykinin-potentiating and C-type natriuretic peptides Proteins 0.000 claims 1
- 229920000858 Cyclodextrin Polymers 0.000 claims 1
- 206010012735 Diarrhoea Diseases 0.000 claims 1
- 208000003790 Foot Ulcer Diseases 0.000 claims 1
- 208000017442 Retinal disease Diseases 0.000 claims 1
- 206010038923 Retinopathy Diseases 0.000 claims 1
- 206010040943 Skin Ulcer Diseases 0.000 claims 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims 1
- 239000002535 acidifier Substances 0.000 claims 1
- 230000002411 adverse Effects 0.000 claims 1
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 claims 1
- 239000003472 antidiabetic agent Substances 0.000 claims 1
- 239000000872 buffer Substances 0.000 claims 1
- 239000003405 delayed action preparation Substances 0.000 claims 1
- 230000003111 delayed effect Effects 0.000 claims 1
- 229940126904 hypoglycaemic agent Drugs 0.000 claims 1
- 239000012729 immediate-release (IR) formulation Substances 0.000 claims 1
- 208000017169 kidney disease Diseases 0.000 claims 1
- 239000011159 matrix material Substances 0.000 claims 1
- 239000012528 membrane Substances 0.000 claims 1
- 201000001119 neuropathy Diseases 0.000 claims 1
- 230000007823 neuropathy Effects 0.000 claims 1
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 claims 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 claims 1
- 230000003204 osmotic effect Effects 0.000 claims 1
- 201000008482 osteoarthritis Diseases 0.000 claims 1
- 208000033808 peripheral neuropathy Diseases 0.000 claims 1
- 239000003087 receptor blocking agent Substances 0.000 claims 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 claims 1
- 239000007787 solid Substances 0.000 claims 1
- 239000004094 surface-active agent Substances 0.000 claims 1
- 238000013268 sustained release Methods 0.000 claims 1
- 239000012730 sustained-release form Substances 0.000 claims 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10893108P | 2008-10-28 | 2008-10-28 | |
| US61/108,931 | 2008-10-28 | ||
| PCT/US2009/062302 WO2010051296A1 (en) | 2008-10-28 | 2009-10-28 | Pharmaceutical compositions containing diacerein |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2012506911A JP2012506911A (ja) | 2012-03-22 |
| JP2012506911A5 true JP2012506911A5 (enExample) | 2012-12-06 |
| JP5642691B2 JP5642691B2 (ja) | 2014-12-17 |
Family
ID=42117735
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011534697A Expired - Fee Related JP5642691B2 (ja) | 2008-10-28 | 2009-10-28 | ジアセレインを含有する医薬組成物 |
Country Status (19)
| Country | Link |
|---|---|
| US (2) | US20100104651A1 (enExample) |
| EP (1) | EP2349289B1 (enExample) |
| JP (1) | JP5642691B2 (enExample) |
| KR (1) | KR101718347B1 (enExample) |
| CN (1) | CN102202673B (enExample) |
| AR (1) | AR073918A1 (enExample) |
| AU (1) | AU2009308958B2 (enExample) |
| BR (1) | BRPI0920255A2 (enExample) |
| CA (1) | CA2741846C (enExample) |
| ES (1) | ES2585904T3 (enExample) |
| IL (1) | IL212483A (enExample) |
| MX (1) | MX2011004395A (enExample) |
| NZ (1) | NZ592376A (enExample) |
| PA (1) | PA8846801A1 (enExample) |
| RU (1) | RU2542461C2 (enExample) |
| SA (1) | SA109300644B1 (enExample) |
| TW (1) | TWI473610B (enExample) |
| UY (1) | UY32204A (enExample) |
| WO (1) | WO2010051296A1 (enExample) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101567925B1 (ko) * | 2010-04-08 | 2015-11-10 | 티더블유아이 바이오테크놀로지 인코포레이티드 | 당뇨병 보조치료요법으로서 디아세레인을 사용하는 방법 |
| CN101822660B (zh) * | 2010-05-13 | 2013-07-10 | 中国人民解放军肾脏病研究所 | 大黄酸类化合物或其盐在制备预防和治疗胰岛β细胞功能衰退药物中的应用 |
| CN103429236B (zh) * | 2011-03-11 | 2016-09-21 | 安成生物科技股份有限公司 | 治疗高尿酸血症和与高尿酸血症相关的代谢性病症的方法和组合物 |
| CN102743370B (zh) * | 2011-06-27 | 2013-05-15 | 王子厚 | 双醋瑞因的用途 |
| JP6224597B2 (ja) * | 2011-09-27 | 2017-11-01 | バイオメッド バレー ディスカバリーズ，インコーポレイティド | グリオーマを処置するための組成物及び方法 |
| EA201491039A1 (ru) * | 2011-12-27 | 2015-02-27 | Сановел Илач Санайи Ве Тиджарет Аноним Ширкети | Комбинации диацереина и нестероидных противовоспалительных лекарственных средств |
| WO2013100881A2 (en) * | 2011-12-27 | 2013-07-04 | Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi | Combined pharmaceutical formulation containing diacerein |
| CN102871982B (zh) * | 2012-10-16 | 2014-09-10 | 中国科学院上海药物研究所 | 一种药物渗透泵制剂 |
| US11198724B2 (en) | 2013-03-14 | 2021-12-14 | The Regents Of The University Of Michigan | Treatment of staphylococcal disorders |
| CN107708681A (zh) * | 2015-04-20 | 2018-02-16 | 安成生物科技股份有限公司 | 含有双醋瑞因的制剂及使用其降低尿酸血液水平的方法 |
| MX373702B (es) * | 2015-07-01 | 2020-05-07 | Twi Biotechnology Inc | Formulaciones topicas de diacereina o rheina y sus usos. |
| US10154984B2 (en) * | 2015-07-01 | 2018-12-18 | Twi Biotechnology, Inc. | Diacerein or Rhein topical formulations and uses thereof |
| US10512625B2 (en) * | 2015-07-01 | 2019-12-24 | Twi Biotechnology, Inc. | Diacerein or rhein topical formulations and uses thereof |
| US10195170B2 (en) * | 2015-08-17 | 2019-02-05 | Twi Biotechnology, Inc. | Methods for inhibiting expression of ASC, expression of NLRP3, and/or formation of NLRP3 inflammasome complex using diacerein or its analogs |
| CN110177547B (zh) * | 2017-01-18 | 2022-09-27 | 台睿生物科技股份有限公司 | 用于治疗炎症性肠病和肠结肠炎的组合物 |
| JP2020505362A (ja) | 2017-01-19 | 2020-02-20 | ティダブリューアイ・バイオテクノロジー・インコーポレイテッドＴＷＩ Ｂｉｏｔｅｃｈｎｏｌｏｇｙ， Ｉｎｃ． | 免疫炎症性皮膚障害を予防または治療するための方法および医薬組成物 |
| EP3459528B1 (en) * | 2017-09-20 | 2022-11-23 | Tillotts Pharma Ag | Preparation of solid dosage forms comprising antibodies by solution/suspension layering |
| CN107929264B (zh) * | 2017-12-04 | 2020-04-24 | 广东药科大学 | 双醋瑞因缓释微球及其制备方法 |
| KR102075724B1 (ko) * | 2018-09-14 | 2020-02-10 | 한국원자력의학원 | 디아세레인을 유효성분으로 포함하는 항체의 종양 침투력 증진용 조성물 및 이의 용도 |
| IL283127B1 (en) | 2018-11-14 | 2026-02-01 | Smilebiotek Zhuhai Ltd | Animal-based models, scanning methods, and methods of treating intraocular diseases or disorders |
| CN110787157A (zh) * | 2019-11-27 | 2020-02-14 | 中南民族大学 | 双醋瑞因在用于舒张预收缩的气管平滑肌及治疗哮喘中的应用 |
| CN113440503B (zh) * | 2021-07-02 | 2022-03-18 | 温州医科大学附属口腔医院 | 超长效可控缓释介孔-透明质酸杂化靶向抗菌纳米材料及其制备方法、用途 |
| CN115227664A (zh) * | 2022-06-27 | 2022-10-25 | 苏州中化药品工业有限公司 | 一种双醋瑞因胶囊及其制备方法与应用 |
| AU2024241638A1 (en) * | 2023-03-28 | 2025-10-09 | Tillotts Pharma Ag | Solid oral dosage form comprising antibodies for sustained release in the lower gastrointestinal tract |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ZA761627B (en) * | 1976-03-16 | 1978-01-25 | C Friedmann | Improvements in or relating to the treatment of arthritis |
| US5569469A (en) * | 1984-10-16 | 1996-10-29 | Vectorpharma International, S.P.A. | Poorly soluble medicaments supported on polymer substances in a form suitable for increasing their dissolving rate |
| US5225192A (en) * | 1988-10-17 | 1993-07-06 | Vectorpharma International S.P.A. | Poorly soluble medicaments supported on polymer substances in a form suitable for increasing their dissolving rate |
| IT1197316B (it) * | 1986-10-01 | 1988-11-30 | Proter Spa | Formulazione galenica ad uso orale di derivati della reina a lento rilascio per impiego terapeutico |
| IT1230566B (it) * | 1988-10-17 | 1991-10-28 | Vectorpharma Int | Farmaci poco solubili supportati su sostanze polimeriche in forma atta all'aumento della velocita' di dissoluzione |
| IT1241417B (it) * | 1990-03-06 | 1994-01-14 | Vectorpharma Int | Composizioni terapeutiche a rilascio controllato di farmaci supportatisu polimeri reticolati e rivestiti con film polimerici,e loro processodi preparazione |
| IT1255522B (it) * | 1992-09-24 | 1995-11-09 | Ubaldo Conte | Compressa per impiego terapeutico atta a cedere una o piu' sostanze attive con differenti velocita' |
| US5840881A (en) * | 1992-11-27 | 1998-11-24 | Takeda Chemical Industries, Ltd. | Composition containing a water-insoluble or slightly water-soluble compound with enhanced water-solubility |
| DK0675710T3 (da) * | 1992-12-23 | 2000-03-27 | Saitec Srl | Fremgangsmåde til fremstilling af farmaceutiske former med styret frigivelse samt de herved opnåede former |
| FR2757397B1 (fr) * | 1996-12-23 | 1999-03-05 | Mazal Pharma | Composition pharmaceutique a base de rheine ou de diacerheine a biodisponibilite amelioree |
| US6197818B1 (en) * | 1998-09-01 | 2001-03-06 | Nanjing General Hospital Of Nanjing Command, Pla | Drug for treating diabetic nephrosis |
| WO2003017997A1 (en) * | 2001-08-25 | 2003-03-06 | Arakis Ltd. | The use of anthroquinones in the treatment of kidney disease |
| FR2842738B1 (fr) * | 2002-07-23 | 2006-02-10 | Negma Lerads | Utilisation d'une rheine pour la preparation d'un medicament pour le traitement de l'inflammation chronique, la prevention et le traitement du rejet des transplantations d'organes et de tissus |
| EP1536788A1 (en) * | 2002-08-30 | 2005-06-08 | Pharmacia Corporation | Pharmaceutical solid dosage forms exhibiting reproductible drug release profile |
| AU2003230189A1 (en) * | 2003-01-29 | 2004-08-23 | Nitin Bhalachandra Dharmadhikari | Oral controlled release pharmaceutical composition containing metaxalone as active agent |
| MXPA04009698A (es) * | 2004-10-04 | 2006-04-05 | Maria Elena Garcia Armenta | Formulaciones farmaceuticas solidas conteniendo diacereina y meloxicam. |
| CN1748675A (zh) * | 2005-07-11 | 2006-03-22 | 丛晓东 | 大黄酸类化合物的复合物及制备方法与治疗糖尿病的应用 |
| US8158152B2 (en) * | 2005-11-18 | 2012-04-17 | Scidose Llc | Lyophilization process and products obtained thereby |
| CN100475201C (zh) * | 2007-03-19 | 2009-04-08 | 上海慈瑞医药科技有限公司 | 二乙酰大黄酸缓释片的制备方法 |
| ES2392781T3 (es) * | 2007-09-27 | 2012-12-13 | Wockhardt Limited | Composiciones farmacéuticas de reína o diacereína |
| WO2009048940A2 (en) * | 2007-10-08 | 2009-04-16 | Dr. Reddy's Laboratories Ltd. | Diacerein pharmaceutical formulations |
-
2009
- 2009-10-07 TW TW98134006A patent/TWI473610B/zh not_active IP Right Cessation
- 2009-10-22 AR ARP090104059A patent/AR073918A1/es not_active Application Discontinuation
- 2009-10-27 SA SA109300644A patent/SA109300644B1/ar unknown
- 2009-10-28 PA PA20098846801A patent/PA8846801A1/es unknown
- 2009-10-28 BR BRPI0920255A patent/BRPI0920255A2/pt not_active IP Right Cessation
- 2009-10-28 US US12/607,251 patent/US20100104651A1/en not_active Abandoned
- 2009-10-28 UY UY0001032204A patent/UY32204A/es not_active Application Discontinuation
- 2009-10-28 RU RU2011121609/15A patent/RU2542461C2/ru not_active IP Right Cessation
- 2009-10-28 KR KR1020117012172A patent/KR101718347B1/ko not_active Expired - Fee Related
- 2009-10-28 ES ES09824084.9T patent/ES2585904T3/es active Active
- 2009-10-28 EP EP09824084.9A patent/EP2349289B1/en not_active Not-in-force
- 2009-10-28 AU AU2009308958A patent/AU2009308958B2/en not_active Ceased
- 2009-10-28 CN CN2009801431098A patent/CN102202673B/zh not_active Expired - Fee Related
- 2009-10-28 CA CA2741846A patent/CA2741846C/en not_active Expired - Fee Related
- 2009-10-28 JP JP2011534697A patent/JP5642691B2/ja not_active Expired - Fee Related
- 2009-10-28 NZ NZ592376A patent/NZ592376A/xx not_active IP Right Cessation
- 2009-10-28 WO PCT/US2009/062302 patent/WO2010051296A1/en not_active Ceased
- 2009-10-28 MX MX2011004395A patent/MX2011004395A/es active IP Right Grant
-
2011
- 2011-04-26 IL IL212483A patent/IL212483A/en active IP Right Grant
-
2013
- 2013-02-15 US US13/768,844 patent/US20130156857A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2012506911A5 (enExample) | ||
| RU2011121609A (ru) | Фармацевтические композиции, содержащие диацереин | |
| KR101241624B1 (ko) | 안지오텐신-ⅱ-수용체 차단제를 포함하는 약제학적 제제 | |
| Gilhotra et al. | A clinical perspective on mucoadhesive buccal drug delivery systems | |
| CA2332790C (en) | Controlled release lipoic acid | |
| JP2013522373A5 (enExample) | ||
| JP2010501607A5 (enExample) | ||
| TW200418453A (en) | Modified release pharmaceutical compositions | |
| JP2007506774A5 (enExample) | ||
| KR101156054B1 (ko) | 안정한 에페리손 함유 서방성 의약조성물 | |
| US20140302125A1 (en) | Methods for treating cardiovascular disorders | |
| AU2012303683A1 (en) | Methods for treating cardiovascular disorders | |
| CA2642851A1 (en) | Low flush niacin formulation | |
| WO2013020416A1 (zh) | 伊伐布雷定或其可药用盐的缓释制剂 | |
| US20030147957A1 (en) | Dual release formulation comprising levodopa ethyl ester and a decarboxylase inhibitor in immediate release layer with levodopa ethyl ester and a decarboxylase inhibitor in a controlled release core | |
| CN108024995A (zh) | 包含塞来昔布及曲马多的药剂学组合物 | |
| TW201035089A (en) | Pharmaceutical composition | |
| CN106983726B (zh) | 阿齐沙坦片及其制备方法 | |
| WO2022225489A1 (en) | A bilayer tablet formulation comprising amorphous dapagliflozin and metformin | |
| CN101642443B (zh) | 单硝酸异山梨酯渗透泵型控释制剂及其制备方法 | |
| CN111818927A (zh) | 用于治疗炎性皮肤疾病的米诺环素 | |
| WO2014096982A1 (en) | Stable pharmaceutical compositions of saxagliptin or salts thereof | |
| WO2025051298A1 (zh) | 一种盐酸伊伐布雷定缓释片及其制备方法 | |
| TW201201800A (en) | A pharmaceutical controlled release composition of losartan | |
| RU2014146936A (ru) | Композиции с немедленным высвобождением лекарственного средства |